Pharmacology in epilepsy. Where are we heading for?;Farmacología en epilepsia. ¿Hacia dónde vamos?

Revista de Neurologia

Volumn 38, Issue 2, 2004, Pages 167-172

  Herranz, J L ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Classical antiepileptic agents; MRP; New antiepileptic agents; P glycoprotein; Pharmacogenomics; Pharmacoresistant

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AMPA RECEPTOR; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CARBAMAZEPINE; CARRIER PROTEIN; CLOBAZAM; CLONAZEPAM; DRUG RECEPTOR; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; GLYCOPROTEIN P; KAINIC ACID RECEPTOR; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SODIUM CHANNEL; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

ABDOMINAL PAIN; APPETITE DISORDER; BRAIN DISEASE; CHANNEL GATING; COGNITIVE DEFECT; CONFERENCE PAPER; CONVULSION; DEPRESSION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG UTILIZATION; EPILEPSY; GINGIVA HYPERPLASIA; HUMAN; HYPERAMMONEMIA; HYPERTRICHOSIS; HYPONATREMIA; LEUKOPENIA; LIVER TOXICITY; MEMORY DISORDER; MENSTRUATION DISORDER; MUSCLE HYPOTONIA; NAUSEA AND VOMITING; NEPHROLITHIASIS; OUTCOMES RESEARCH; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PROTEIN EXPRESSION; RASH; SKIN ALLERGY; SOMNOLENCE; TECHNIQUE; VISUAL DISORDER;

EID: 1342333376     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3802.2003451     Document Type: Conference Paper

References (31)

1. Armijo JA, Herranz JL. Fármacos antiepilépticos y anticonvulsivos. In Flórez J, Armijo JA, Mediavilla A, eds. Farmacología humana. 4 ed. Masson: Barcelona; 2003. p. 517-41.
2. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24: 91-103.
3. Herranz JL. Factores clínicos, farmacológicos y sociales que modulan el tratamiento de los niños con epilepsia. Bol Pediatr 2002; 42: 230-40.
4. Wallace SJ. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 2001; 23: 277-83.
5. Perucca E. Marketed new antiepileptic drugs: are they better than old-generation agents? Ther Drug Monit 2002; 24: 74-80.
6. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999; 33: 247-62.
7. Gil-Nagel A. Review of new antiepileptic drugs as initial therapy. Epilepsia 2003; 44 (Suppl. 4): S3-10.
8. Armijo JA, Adin-Ibarra J, Sánchez-Baglietto N, Vega-Gil N. Monitorización de los niveles séricos de los nuevos antiepilépticos. Rev Neurol 2002; 35 (Supl 1): S116-34.
9. Bialer M, Johannessen SI, Kupfenberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth EILAT Conference (EILAT VI). Epilepsy Res 2002; 51: 31-71.
10. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.
11. Löscher W, Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Res 2002; 50: 3-16.
12. Deckers CLP, Genton P, Sills GJ, Schmidt D. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res 2003; 53: 1-17.
13. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002; 301: 7-14.
14. Glauser TA. Advancing the medical management of epilepsy: disease modification and pharmacogenetics. J Chils Neurol 2001; 17 (Suppl 1): S85-93.
15. Evans WE, McLeod HL. Pharmacogenomics -drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
16. Varadi A, Szakacs G, Bakos E, Sarkadi B. P glycoprotein and the mechanism of multidrug resistance. In Novartis Foundation, eds. Mechanisms of drug resistance in epilepsy: lessons from oncology. Symposium 243. Chichester: John Wiley; 2002. p. 54-68.
17. Fromm MF. P-glycoprotein a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000; 38: 69-74.
18. Borst P, Evers R, Kool M, Wijdholds J. The multidrug resistance protein family. Biochim Biophys Acta 1999; 1461: 347-57.
19. Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res 1999; 126: 509-16.
20. Abbot NJ, Khan EU, Rollinson MS, Reichel A, Janigro D, Dombrowski SM, et al. Drug resistance in epilepsy: the role of the blood-brain barrier. In Novartis Foundation, eds. Mechanisms of drug resistance in epilepsy: lessons from oncology. Symposium 243. Chichester: John Wiley; 2002. p. 38-47.
21. Wijnholds J. Drug resistance caused by multidrug resistance-associated proteins. In Novartis Foundation, eds. Mechanisms of drug resistance in epilepsy: lessons from oncology, Symposium 243, Chichester: John Wiley; 2002. p. 69-79.
22. Seegers U, Potschka H, Löscher W. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdale-kindled rats. Epilepsia 2002; 43: 675-84.
23. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001; 42: 1501-6.
24. Sisodiya SM, Lin WR, Harding BN, Squier MV, Keir G, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125: 22-31.
25. Potschka H, Löscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001; 42: 1231-40.
26. Newman MJ, Dixon R, Toyonaga B. OC 144-093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy. In Novartis Foundation, eds. Mechanisms of drug resistance in epilepsy: lessons from oncology. Symposium 243. Chichester: John Wiley; 2002. p. 213-26.
27. Herranz JL. Epilepsia mioclónica grave de la infancia (síndrome de Dravet). Aspectos genéticos. Rev Neurol 2003; 37: 60-3.
28. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999; 34: 109-22.
29. Ramachandran V, Shorvon SD. Clues of the genetic influences of drug responsiveness in epilepsy. Epilepsia 2003; 44 (Suppl 1): S33-7.
30. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001; 2: 51-64.
31. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348: 1442-8.